QualityAssuranceUnexpectedEventsListedness/expectednessGlobalSafetyDatabaseprocessexcellencebackgroundratesValidatedSignalInformedConsentWorld HealthOrganizationSafetyInformationProductQualityComplaintPVAgreementClinicalStudyNumberLabeledorunlabeledGoodPharmacovigilancePracticeNon-seriousAESIInvestigationalMedicinalProductSignalValidationPharmacovigilanceSafetySignalSuspectedUnexpectedSeriousAdverseReaction(SUSAR)PharmacovigilanceSystem MasterFileOrganizedDataCollectionProgramAffiliateDrugAdverseEventReportingSystemSignalDetectionOverdoseIdentifiedRiskSignalAssessmentContractResearchOrganization(CRO)BusinessPartnerDevelopmentSafetyUpdateReportDevelopmentalRiskManagementPlanCountrySafetyLead/ManagerProtocolClinicalStudyMedicinesandHealthcareRegulatoryAgencyDrugProductProductRecallPharmacovigilanceAdverseEvent(AE)ReferenceSafetyInformationGVPModuleIRisk-BenefitBalanceCouncil forInternationalOrganizationsof MedicalSciencesChiefSafetyOfficerBenefit-riskanalysisOccupationalexposureInternationalConferenceonHarmonization(ICH)TolerabilityMedicalReviewDevelopmentInternationalBirth DateUrgentSafetyMeasureInvestigatorBeiGeneRepresentativePatientSafetyCompanySafetyCommitteeRiskCommunicationAdverseEvent ofSpecialInterest(AESI)PeriodicSafetyUpdateReportInterventionalStudyperiodicsafetyupdatereport(PSUR)PharmacoepidemiologySignalPrioritizationOff-labeluseGlobalPatientSafetyProductSafetyStrategyAdverseDrugReaction(ADR)SponsorSafetyAssessmentTeamalliancemanagementSignalDetectionPlanObservationalstudyMarketingAuthorizationHolderInvestigator’sBrochureRiskManagementAdverseEventReportNumberPost-authorizationSafety StudyImportantPotentialRisksNationalMedicalProductAdministrationDearInvestigatorLetterSpecialSituationsDrugSubstanceGoodClinicalPracticePeriodicBenefit-RiskEvaluationReportPharmacovigilanceSystemBusinessContinuityPlanCompanyCoreSafetyInformationNon-InterventionalStudyAggregateSafetyReport(ASR)EudraVigilanceSpontaneous(Unsolicited)reportHealthAuthorityClinicalDevelopmentProgramCausalityAssessmentIndividualCaseSafetyReportCompanyCore DataSheetSolicitedreportsBlindingorMaskingCorrectiveandPreventiveAction(CAPA)IndividualCase SafetyReport(ICSR)InvestigationalNew DrugApplicationLiteratureReportMedicalDictionary forRegulatoryActivities(MedRA)Local SafetyRepresentativeClinicalTrialApplicationExpectednessRiskManagementPlanInstitutionalReviewBoardSafetyDataExchangeAgreementNon-validatedsignalSignalManagementProcessPost-MarketingSurveillanceSafetyManagementTeamNew DrugApplicationRegulatoryauthorityOtherSafetyIssueSubjectMatterExpertMonitoringPlanSeriousAdverseEventClinicalTrialRefutedSignalDrugAbuseDataLockPointHealthcareProfessionalProductComparatorProductQualified PersonforPharmacovigilanceSideeffectQualityManagementSystem(QMS)QualityAssuranceUnexpectedEventsListedness/expectednessGlobalSafetyDatabaseprocessexcellencebackgroundratesValidatedSignalInformedConsentWorld HealthOrganizationSafetyInformationProductQualityComplaintPVAgreementClinicalStudyNumberLabeledorunlabeledGoodPharmacovigilancePracticeNon-seriousAESIInvestigationalMedicinalProductSignalValidationPharmacovigilanceSafetySignalSuspectedUnexpectedSeriousAdverseReaction(SUSAR)PharmacovigilanceSystem MasterFileOrganizedDataCollectionProgramAffiliateDrugAdverseEventReportingSystemSignalDetectionOverdoseIdentifiedRiskSignalAssessmentContractResearchOrganization(CRO)BusinessPartnerDevelopmentSafetyUpdateReportDevelopmentalRiskManagementPlanCountrySafetyLead/ManagerProtocolClinicalStudyMedicinesandHealthcareRegulatoryAgencyDrugProductProductRecallPharmacovigilanceAdverseEvent(AE)ReferenceSafetyInformationGVPModuleIRisk-BenefitBalanceCouncil forInternationalOrganizationsof MedicalSciencesChiefSafetyOfficerBenefit-riskanalysisOccupationalexposureInternationalConferenceonHarmonization(ICH)TolerabilityMedicalReviewDevelopmentInternationalBirth DateUrgentSafetyMeasureInvestigatorBeiGeneRepresentativePatientSafetyCompanySafetyCommitteeRiskCommunicationAdverseEvent ofSpecialInterest(AESI)PeriodicSafetyUpdateReportInterventionalStudyperiodicsafetyupdatereport(PSUR)PharmacoepidemiologySignalPrioritizationOff-labeluseGlobalPatientSafetyProductSafetyStrategyAdverseDrugReaction(ADR)SponsorSafetyAssessmentTeamalliancemanagementSignalDetectionPlanObservationalstudyMarketingAuthorizationHolderInvestigator’sBrochureRiskManagementAdverseEventReportNumberPost-authorizationSafety StudyImportantPotentialRisksNationalMedicalProductAdministrationDearInvestigatorLetterSpecialSituationsDrugSubstanceGoodClinicalPracticePeriodicBenefit-RiskEvaluationReportPharmacovigilanceSystemBusinessContinuityPlanCompanyCoreSafetyInformationNon-InterventionalStudyAggregateSafetyReport(ASR)EudraVigilanceSpontaneous(Unsolicited)reportHealthAuthorityClinicalDevelopmentProgramCausalityAssessmentIndividualCaseSafetyReportCompanyCore DataSheetSolicitedreportsBlindingorMaskingCorrectiveandPreventiveAction(CAPA)IndividualCase SafetyReport(ICSR)InvestigationalNew DrugApplicationLiteratureReportMedicalDictionary forRegulatoryActivities(MedRA)Local SafetyRepresentativeClinicalTrialApplicationExpectednessRiskManagementPlanInstitutionalReviewBoardSafetyDataExchangeAgreementNon-validatedsignalSignalManagementProcessPost-MarketingSurveillanceSafetyManagementTeamNew DrugApplicationRegulatoryauthorityOtherSafetyIssueSubjectMatterExpertMonitoringPlanSeriousAdverseEventClinicalTrialRefutedSignalDrugAbuseDataLockPointHealthcareProfessionalProductComparatorProductQualified PersonforPharmacovigilanceSideeffectQualityManagementSystem(QMS)

Untitled Bingo - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
  1. Quality Assurance
  2. Unexpected Events
  3. Listedness/ expectedness
  4. Global Safety Database
  5. process excellence
  6. background rates
  7. Validated Signal
  8. Informed Consent
  9. World Health Organization
  10. Safety Information
  11. Product Quality Complaint
  12. PV Agreement
  13. Clinical Study Number
  14. Labeled or unlabeled
  15. Good Pharmacovigilance Practice
  16. Non-serious AESI
  17. Investigational Medicinal Product
  18. Signal Validation
  19. Pharmacovigilance
  20. Safety Signal
  21. Suspected Unexpected Serious Adverse Reaction (SUSAR)
  22. Pharmacovigilance System Master File
  23. Organized Data Collection Program
  24. Affiliate
  25. Drug Adverse Event Reporting System
  26. Signal Detection
  27. Overdose
  28. Identified Risk
  29. Signal Assessment
  30. Contract Research Organization (CRO)
  31. Business Partner
  32. Development Safety Update Report
  33. Developmental Risk Management Plan
  34. Country Safety Lead/Manager
  35. Protocol
  36. Clinical Study
  37. Medicines and Healthcare Regulatory Agency
  38. Drug Product
  39. Product Recall
  40. Pharmacovigilance
  41. Adverse Event (AE)
  42. Reference Safety Information
  43. GVP Module I
  44. Risk-Benefit Balance
  45. Council for International Organizations of Medical Sciences
  46. Chief Safety Officer
  47. Benefit-risk analysis
  48. Occupational exposure
  49. International Conference on Harmonization (ICH)
  50. Tolerability
  51. Medical Review
  52. Development International Birth Date
  53. Urgent Safety Measure
  54. Investigator
  55. BeiGene Representative
  56. Patient Safety
  57. Company Safety Committee
  58. Risk Communication
  59. Adverse Event of Special Interest (AESI)
  60. Periodic Safety Update Report
  61. Interventional Study
  62. periodic safety update report (PSUR)
  63. Pharmacoepidemiology
  64. Signal Prioritization
  65. Off-label use
  66. Global Patient Safety
  67. Product Safety Strategy
  68. Adverse Drug Reaction (ADR)
  69. Sponsor
  70. Safety Assessment Team
  71. alliance management
  72. Signal Detection Plan
  73. Observational study
  74. Marketing Authorization Holder
  75. Investigator’s Brochure
  76. Risk Management
  77. Adverse Event Report Number
  78. Post-authorization Safety Study
  79. Important Potential Risks
  80. National Medical Product Administration
  81. Dear Investigator Letter
  82. Special Situations
  83. Drug Substance
  84. Good Clinical Practice
  85. Periodic Benefit-Risk Evaluation Report
  86. Pharmacovigilance System
  87. Business Continuity Plan
  88. Company Core Safety Information
  89. Non-Interventional Study
  90. Aggregate Safety Report (ASR)
  91. EudraVigilance
  92. Spontaneous (Unsolicited) report
  93. Health Authority
  94. Clinical Development Program
  95. Causality Assessment
  96. Individual Case Safety Report
  97. Company Core Data Sheet
  98. Solicited reports
  99. Blinding or Masking
  100. Corrective and Preventive Action (CAPA)
  101. Individual Case Safety Report (ICSR)
  102. Investigational New Drug Application
  103. Literature Report
  104. Medical Dictionary for Regulatory Activities (MedRA)
  105. Local Safety Representative
  106. Clinical Trial Application
  107. Expectedness
  108. Risk Management Plan
  109. Institutional Review Board
  110. Safety Data Exchange Agreement
  111. Non-validated signal
  112. Signal Management Process
  113. Post-Marketing Surveillance
  114. Safety Management Team
  115. New Drug Application
  116. Regulatory authority
  117. Other Safety Issue
  118. Subject Matter Expert
  119. Monitoring Plan
  120. Serious Adverse Event
  121. Clinical Trial
  122. Refuted Signal
  123. Drug Abuse
  124. Data Lock Point
  125. Healthcare Professional
  126. Product
  127. Comparator Product
  128. Qualified Person for Pharmacovigilance
  129. Side effect
  130. Quality Management System (QMS)